Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 184,107

Document Document Title
WO/2021/092115A1
The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2021/088885A1
The present invention relates to the technical field of chemical medicine, in particular to a compound targeting type I PRMT, a preparation method therefor, and an application thereof. The compound A and a pharmaceutically acceptable sal...  
WO/2021/090320A1
A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeuti...  
WO/2021/067863A3
The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD- L1.  
WO/2021/091904A1
Aspects of the disclosure include methods for treating a myeloproliferative neoplasm. Methods according to certain embodiments include co-administering to a subject a Janus kinase (JAK) inhibitor and a telomerase inhibitor comprising an ...  
WO/2021/092030A1
The invention described herein relates to methods for treating a human subject with myelofibrosis or an MPN-related disorder, comprising administering navitoclax to the subject optionally in combination with ruxolitinib.  
WO/2021/092060A1
The disclosure relates to multispecific antibodies against BCMA for use in the treatment of lymphoma, such as non-Hodgkin's Lymphoma (NHL).  
WO/2021/088845A1
An imidazolidinone compound as represented by formula (I) or a stereoisomer, a geometric isomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthetic metho...  
WO/2021/092471A1
Provided herein are compositions comprising a vaccine composition and an agent that triggers metabolic reprogramming of B cells and methods of using the agent that triggers metabolic reprogramming of B cells to increase effectiveness of ...  
WO/2021/088838A1
Provided are a binding molecule specifically for CD39 and the use thereof. Specifically, provided are an antibody that binds to CD39 and inhibits the activity of CD39 or an antigen binding part thereof, the use of the antibody or the ant...  
WO/2021/089828A1
Provided is a compound for use in preventing, treating or delaying progression of a disease involving aberrant fibroblast proliferation. The compound is a compound effective in reducing the level of 5 tyrosine phosphatase activity effect...  
WO/2021/092110A1
The present invention is related to a nuclease-activated culture substrate, a method of rapidly detecting an antibiotic-resistant microorganism using the nuclease-activated culture substrate, and kits including the nuclease-activated cul...  
WO/2021/088787A1
Disclosed is a quinazoline compound used as an AXL inhibitor. The structure of the quinazoline compound is as shown in general formula (I), and the definition of each substituent is as described in the description. Further provided is a ...  
WO/2021/092593A1
Disclosed herein is a chimeric antigen receptor T cell therapy for treating patients having a cancer, such as a cancer having one or more solid tumors. Described herein are improved methods for enhancing CAR T cell trafficking and persis...  
WO/2021/091964A1
Provided is a method of treating a distal tumor in an individual by administering a chimeric poliovirus to a first tumor in an effective amount to induce an antitumor immune response effective to treat a distal tumor.  
WO/2021/091958A1
The present disclosure provides RIG-I antagonists. In certain embodiments, the antagonists of the disclosure can be used to treat or prevent a disease or disorder in a subject.  
WO/2021/091358A1
The present invention relates to a pharmaceutical composition for the prevention or treatment of a disease, disorder, or condition associated with Nurr1, including, as an active ingredient, a prostaglandin analog or a pharmaceutically ac...  
WO/2021/089513A1
The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/WT1 x CD3 bispecific antibody and lenalidomide.  
WO/2021/091956A1
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.  
WO/2021/091960A1
Methods of treating cancer with anti-PD-1 antibodies are provided.  
WO/2021/089794A1
The invention provides a platinum-based agent (e.g., carboplatin) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in methods of treating cancer, such as bladder canc...  
WO/2020/140005A8
The present invention relates to compounds of Formula (II) and more preferably to 1H-pyrrolo[2,3-b]pyridine derivatives of formula (III) and related compounds. The variables are defined in the claims. The compounds are BCL-2 inhibitors f...  
WO/2021/088983A1
Disclosed is a 7,8-dihydroxyflavone composite nano-biomaterial with high bioavailability, a preparation method thereof, and an application thereof Specifically, the material uses zein and lactoferrin as packaging material and uses 7,8-di...  
WO/2021/092236A1
Methods and systems for deconvoluting tumor ecosystems for personalized cancer therapy are disclosed. Generally, human cancers exhibit large variation in behavior between and within patients, which is in large part related to cellular co...  
WO/2021/064137A3
The present invention relates to novel B7H6/CD3 binding proteins. The invention also relates to nucleic acids encoding such proteins; to methods for preparing such proteins; to host cells expressing or capable of expressing such proteins...  
WO/2021/092081A1
Dual receptor binding compounds comprising IL-2Rβ, IL-7Rα, and Ryc ligands, and pharmaceutical compositions comprising the dual receptor binding compounds are disclosed. The dual receptor binding compounds can act as IL-2R and IL-7R ag...  
WO/2021/090855A1
The following were discovered: a cyclic peptide compound that interacts with Ras; and an unnatural amino acid that is useful in the production of said cyclic peptide compound. The cyclic peptide compound was also discovered to inhibit bo...  
WO/2021/090321A1
A method of treating or preventing a T cell mediated autoimmune disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subje...  
WO/2021/089790A1
The present invention relates to compounds having a lipid affinity of less than 15% by weight of the compound (such as a logP of -0.75 or less) for use in targeting mitochondria to reduce, inhibit or prevent the formation of mitochondria...  
WO/2021/088957A1
Disclosed are a novel aromatic heterocyclic compound as an ATX (Autotaxin) inhibitor, a pharmaceutical composition containing the compound, and a use of the compound and the composition in treatment of a disease having a pathological cha...  
WO/2021/062405A3
Methods comprising a step of administering, to a mammalian male subject, a composition comprising α-lactalbumin for the treatment of male breast cancer.  
WO/2021/091906A1
The present invention relates to treatment methods for leukemia using bispecific antibody constructs that specifically bind to human CD33 and human CD3. In particular, the present invention relates to methods for treating myeloid leukemi...  
WO/2021/092134A1
The present invention provides a method for the treatment of DLL3-positive cancer or SCLC, comprising administering to a subject in need thereof an anti-DLL3 agent at a dose of between about 0.3 mg to about 100 mg or between about 3 mg t...  
WO/2021/089715A1
Use of colchicine to inhibit, delay, or reduce the occurrence of lung cancer in a subject with cancer, comprising administering to the subject an effective amount of colchicine is provided.  
WO/2021/089588A1
The disclosure provides methods and compositions for treating tumors, particularly HER2- positive tumors. The method comprises administering a therapeutically effective amount of a HER2/4-1BB bispecific fusion protein. The HER2/4-1BB bis...  
WO/2021/092171A1
Disclosed herein are diagnostic and therapeutic methods for the treatment of hematologic cancers, including multiple myeloma (MM), as well as related compositions. In particular, the invention relates to diagnostic and therapeutic method...  
WO/2021/091107A1
The present invention relates to a pharmaceutical composition for enhancing radiation sensitivity containing ageloxime D as an active ingredient, and a composition for aiding anticancer treatment, wherein the ageloxime D increases the ra...  
WO/2021/092543A1
Provided are methods for treating a disease, disorder, or condition associated with an acid ceramidase (AC) biological activity. The methods include administering to a subject in need thereof a composition including an AC inhibitor and a...  
WO/2021/091605A1
The present invention is directed to combination treatments with anti-PVRIG antibodies and anti-PD-1 antibodies, in particular nivolumab, using stable liquid pharmaceutical formulations thereof.  
WO/2021/089038A1
Disclosed is the use of a multi-target protein kinase inhibitor compound A or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating leukemia, and a method of using compound A to treat acute myeloid leukemia...  
WO/2021/090146A1
The present disclosure provides methods of treating cancer in a patient. The method comprises administering to the patient an effective amount of a compound of Formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof, and an e...  
WO/2021/090183A1
The present invention related to a stable liquid pharmaceutical composition comprising melphalan or its pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, wherein the said stable liquid pharm...  
WO/2021/091272A1
Disclosed are a composition for inducing immunity against an active ingredient and a method for preparing same, the composition comprising: a nucleic acid, a polypeptide, or a combination thereof as the active ingredient; a cationic comp...  
WO/2021/091560A1
The present disclosure concerns combination therapy for cancer that utilizes (i) an oncolytic virus; (ii) a virus comprising nucleic acid encoding an immunomodulatory factor; and (iii) at least one cell comprising a chimeric antigen rece...  
WO/2021/090272A1
The invention provides an anti-PD-1 antibody comprising the complementary determining regions (CDRs) of pembrolizumab in combination with an antibody-drug conjugate that binds to tissue factor (TF) comprising monomethyl auristatin E and ...  
WO/2021/090245A1
The present technology provides pyrrolidine and piperidine compounds or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. In particular, said comp...  
WO/2021/090062A1
Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in...  
WO/2021/089791A1
Resistance to kinase inhibitors exemplifies the greatest hindrance to effective treatment of cancer patients. Recent studies have suggested that the onset of said resistance might not only be explained by a drug selection of pre-existing...  
WO/2021/088839A1
An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a ...  
WO/2021/088945A1
The present invention falls within the field of medical chemistry and relates to a class of compounds as SHP2 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (I), or an isome...  

Matches 1 - 50 out of 184,107